Advanced search
Publication Cover
Acta Oncologica Volume 58, 2019 - Issue 1
Journal homepage
803
Views
0
CrossRef citations to date
0
Altmetric
LETTERS TO THE EDITOR: MEDICAL ONCOLOGY

Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword

Ahmet Emre EskazanDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-9568-0894
ORCID Icon
Pages 123-124 | Received 11 Jun 2018, Accepted 16 Jul 2018, Published online: 14 Aug 2018

References

  • Steegmann JL, Cervantes F, le Coutre P, et al. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012;53:2351–2361.
  • Langberg MK, Berglund-Nord C, Cohn-Cedermark G, et al. Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA. Acta Oncol. 2018;1–6. 5:doi:10.1080/0284186X.2018.1479072.
  • Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, et al. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin’s lymphoma: hope for severe chemotherapy-induced toxicity? J Clin Oncol. 2011;29:e691–e693.
  • Banakh I, Lam A, Tiruvoipati R, et al. Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence-base review. Clin Case Rep. 2016;4:486–490.
  • Baird K, Comis LE, Joe GO, et al. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:1083–1090.
  • Eşkazan AE, Salihoğlu A, Erturan S, et al. Interstitial pneumonitis in a patient with chronic myeloid leukemia. Turk J Haematol. 2013;30:435–436.
  • Go SW, Kim BK, Lee SH, et al. Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis. Tuberc Respir Dis. 2013;75:256–259.
  • Luo ZB, Xu N, Huang XP, et al. Imatinib-induced interstitial pneumonitis successfully switched to nilotinib in a patient with prior history of mycobacterium tuberculosis infection. Turk J Haematol. 2017;34:362–364.
  • Ohnishi K, Sakai F, Kudoh S, et al. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006;20:1162–1164.
  • Yamasawa H, Sugiyama Y, Bando M, et al. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration. 2008;75:350–354.
  • Snyder LS, Hertz MI, Peterson MS, et al. Acute lung injury. Pathogenesis of intraalveolar fibrosis. J Clin Invest. 1991;88:663–673.
  • Walsh J, Absher M, Kelley J. Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol. 1993;9:637–644.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.